



Project full title:
Hepatic and Cardiac Toxicity Systems modelling

Project acronym:
HeCaTos

Collaborative project
HEALTH.2013.1.3.-1:
Modelling toxic response in case studies for predictive human safety assessment

FP7-HEALTH-2013-INNOVATION-1-602156-HeCaTos

**Deliverable Report D14.1:
Kick-off Meeting**

Work package 14

Due date of deliverable: M1
Actual submission date: December 2013

Start date of project: October, 2013

Duration: 60 months

Maastricht University (UM)

Project co-funded by the European Commission within the 7th Framework Programme (2013-2018)		
Dissemination Level		
PU	Public	X
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, only for members of the consortium (including the Commission Services)	

Contributions to deliverable - Internal review procedure

Deliverable produced by:	Date:
Sandrien Wansink (UM)	October 2013
Rene Reijnders (UM)	November 2013
Deliverable internally reviewed by:	Date:
Jos Kleinjans (UM)	November 2013

Contents

Summary	2
Agenda Thursday - October 3, 2013	6
Agenda Friday - October 4, 2013	7
HeCaToS kick off meeting: agreement on next steps	8

SUMMARY

HeCaToS is Collaborative Project, Large-scale integrating project. Grant Agreement No.: HEALTH-F4-2013-602156

Work programme topic addressed: HEALTH.2013.1.3.-1: Modelling toxic response in case studies for predictive human safety assessment FP7-HEALTH-2013-INNOVATION-1

The kick-off of the HeCaToS project was held on October 3-4, 2013 at Amrâth Grand Hotel de l'Empereur, Maastricht, the Netherlands. All Project partners attended the Kick-off meeting.

Final Agenda HeCaTos Kick-off Meeting

Venue:

Amrâth Grand Hotel de l'Empereur
Stationsstraat 2
6221BP Maastricht
www.amrathgrandhotelempereur.nl

Hepatic and Cardiac Toxicity Systems Modelling

Collaborative Project

Large-scale integrating project

Grant Agreement No.: HEALTH-F4-2013-602156

Work programme topic addressed:

**HEALTH.2013.1.3.-1: Modelling toxic response in case studies for predictive human safety assessment
FP7-HEALTH-2013-INNOVATION-1**



Amrâth Grand Hotel de l'Empereur

How to get there/directions:

Hotel accommodation

Amrâth Grand Hotel de l'Empereur
Stationsstraat 2, 6221BP Maastricht
Phone: +31 43 326 21 85
E-mail: reservering@hotel-empereur.nl
www.hotel-empereur.nl

We kindly ask you to use the registration form of the hotel to book your room.

Transport

By plane

Airport Maastricht-Aachen is the closest airport. We advise you to take a taxi from airport Maastricht-Aachen to the hotel.
Other airports nearby are Brussels, Düsseldorf, Cologne or Eindhoven (NL).

By car

Coming via the A2/E25, follow the signs to 'Wijk 21' and 'Station'. Amrâth Grand Hotel de l'Empereur is located right opposite the central railway station.

Parking facilities

In front of the hotel there is a loading/unloading zone where you can park your car (hazard warning lights on) to check in. The hotel has a private parking. Due to limited capacity, please make a reservation prior to arrival.

Alternatives: 4 Q-Park garages reachable within walking distance

Parking fees are € 18,50 per car/ night (maximum car height is 1.90 m.) to 12.30 pm of the day of departure. For any additional hours, € 1,75 per hour is charged.

Public transport

Amrâth Grand Hotel de l'Empereur is located directly opposite the Maastricht central railway station.

For timetables of the Dutch railways check: <http://www.ns.nl/en/travellers/home>


Dinner

A dinner will be offered on Thursday the 3th October at 19:30 pm at restaurant Crowne Plaza Hotel, Ruiterij 1, 6221 EW Maastricht.

A 10 minutes' walk from the meeting location. If you have any special dietary restrictions please indicate that the registration form.

A = Amrâth Grand Hotel de l'Empereur (meeting site and hotel)

B = Crowne Plaza Hotel (dinner)



AGENDA THURSDAY - OCTOBER 3, 2013

09:30	Registration and coffee
10:00	Welcome and Overview EU-FP7 HeCaTos Project by Jos Kleinjans, Coordinator HeCaTos Maastricht University
10:30	Welcome by: Prof. dr. Luc Soete, Rector Magnificus Maastricht University
10:45	Welcome by Christian Desaintes, Scientific Officer, DG Research & Innovation European Commission
11:00	Introduction round HeCaTos partners and Members Scientific Advisory Committee
11:30	Management outline HeCaTos Project
12:30	<i>Lunch break</i>
	<i>Presentation of WPs (RTD, WPs 1 to 13) 30 min's per WP including discussion (WP leader and consortium partners)</i>
13:30	SUB-PROJECT “Multi-scale modelling” introduction by Nic Smith King’s College London
13:40	WP1 Computational chemistry: Matt Segal Optibrium
14:10	WP2 Molecular pathway modelling: Johannes Schuchhardt MicroDiscovery
14:40	WP3 Physiological modelling: Nic Smith King’s College London
15:10	WP4 Vertical model integration: Lars Kuepfer RWTH Aachen
15:35	<i>Coffee break</i>
16:10	SUB-PROJECT 2 “Samples” introduction by José Castell Hospital Universitario HULAFE
16:30	WP5 <i>in vitro</i> 3D assays: Adrian Roth Hoffmann-La Roche
17:00	WP6 Patients: Stephane Heymans Maastricht University
17:30	End of first day
19:30	Dinner, Crowne Plaza Hotel Maastricht

AGENDA FRIDAY - OCTOBER 4, 2013

09:00	Opening & introduction Day 2 by Jos Kleinjans Maastricht University
09:15	SUB-PROJECT 3 “Analyses” introduction by Jos Kleinjans Maastricht University
09:30	WP7 ‘Omics analyses Ralf Schlapbach ETH Zürich
10:00	WP8 Functional analyses James Hynes LuxCel Biosciences Ltd
10:30	<i>Coffee break</i>
10:45	SUB-PROJECT 4 “Data Infrastructure” introduction by Timo Wittenberger Genedata
11:00	WP9 Data warehousing: John Overington EMBL
11:30	WP10 Data quality control: Hans Gmuender Genedata
12:00	WP11 Integrated statistics: Ralf Herwig MPIMG
12:30	<i>Lunch break</i>
13:30	WP12 PREDICTIVE COMPARISONS by Ralf Herwig MPIMG
14:00	WP13 Training and Dissemination by Hector Keun Imperial College London
14:30	Now Role for an Old Receptor: AHR Function in Hepatic Progenitor Cells by Russell Thomas National Centre for Computational Toxicology US EPA
15:30	<i>Coffee break</i>
15:45	Open discussion & conclusions HeCaTos Kick-off meeting
16:30	Closure HeCaTos Kick-off Meeting

HeCAToS KICK OFF MEETING: AGREEMENT ON NEXT STEPS

1. Compounds selection - part 1

A Task Force will be set in place by WPs 5 and 6 under coordination of Adrian Roth, for the purpose of selecting prototypical compounds, with clinical relevance/use as an important selection criterium. An important issue is to select those prototypical liver and heart toxicants which would be really relevant for in depth investigations of mechanisms-of-action, while the remained of the selection list will be subjected to broader studies.

Other important decisions to be made refer to doses to be applied in vitro (based on clinical c_{max} as derived through PBPK modeling where WP 3, Lars Kuepfer, may help), as well as to temporal dependencies to be studied, where for modeling purposes, WPs 2-4 will strongly benefit from time series-derived data. With respect to clinical relevance, an issue to be settled is whether we will be focusing on acute or chronic toxicity.

Preliminary conclusions to be reported at the forthcoming Project Board meeting

2. Intracellular measurements

Intracellular measurements of mother compounds and/or metabolites would provide highly relevant data for molecular dynamics (WP1) and PBPK modeling (WP4). WP7 (Hector Keun) will evaluate possibilities here.

Conclusions to be reported at the forthcoming Project Board meeting

3. Compounds selection - part 2

Once compounds have been selected, WP1 (MD, ChEMBL) and WP2 can already start developing initial models based on literature data related to transmembrane transport, drug-target interactions and molecular mechanisms-of-action, thereby focusing on mitochondrial injury Sample size spheroids/patients

4. Sample size spheroids/patients

WPs 7 and 8 under coordination of Jos Kleinjans will continue completing the presented spread sheet depicting requesting numbers of cell/biopsy sizes for foreseen omics/functional analysis

Preliminary conclusions to be reported at the forthcoming Project Board meeting

5. Idiosyncrasy

It was decided not to genotype patients.